Filing Flows › Vir Biotechnology (VIR) › Q2 2026
Vir Biotechnology (VIR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Vir Biotechnology (VIR) reported revenue of $239M for the second quarter 2026 (Q2 2026), up 197-fold from a year earlier. Operating margin was 30.7%, net earnings $80.1M (33.5% of revenue).
Vir Biotechnology, Q2 2026: revenue $239M (197× year over year), operating margin 30.7%, net earnings $80.1M, operating cash flow $123M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $239M | — | 197× |
| Operating profit | $73.5M | — | — |
| Net earnings | $80.1M | — | — |
| Operating cash flow | $123M | — | — |
| Free cash flow | $123M | — | — |
What changed
Revenue was $238.9M in Q2 2026, up 19583% year over year. License and collaboration revenue was the largest line at 100% of revenue. License and collaboration revenue added $239.4M year over year, 101% of the total change. Grant revenue declined 94%.
Operating profit was $73.5M, a 30.7% margin (up 9785.0 points year over year). Total costs grew 38% against revenue growth of 19583%. The fastest-growing cost line was Research & development (+39%). Net earnings were $80.1M. The effective tax rate was 0.2%.
Operating cash flow was $123.3M, 154% of net earnings. Non-cash charges added back $2.8M of depreciation and amortization and $12.4M of share-based compensation. Working capital and other items added $28.1M. Capital expenditures of $32K left free cash flow of $123.3M.
Questions
What was Vir Biotechnology's revenue in the second quarter 2026?
Vir Biotechnology (VIR) reported revenue of $239M for the second quarter 2026 (Q2 2026), up 197-fold from a year earlier.
Was Vir Biotechnology profitable in the second quarter 2026?
Operating profit was $73.5M (30.7% of revenue) and net earnings $80.1M.
Source: Vir Biotechnology 10-Q on SEC EDGAR.